{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-133759","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.069071+00:00","generated_at":"2026-06-02T14:48:37.208017+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Teva Q1 revenue $3.8B (+4% YoY), non-GAAP EPS $0.48, reaffirms FY24 guidance","bullets":["Revenue $3.819B (+4% YoY, +5% local currency); generics up 9% globally.","AUSTEDO U.S. sales up 67% YoY; AJOVY $113M (+18% YoY).","Non-GAAP diluted EPS $0.48 (vs $0.40); GAAP loss per share $0.12 (vs $0.20 loss).","FY2024 guidance reaffirmed: revenue $15.7-16.3B, non-GAAP EPS $2.20-2.50, free cash flow $1.7-2.0B.","Positive Phase 3 efficacy results for olanzapine LAI (TEV-749) for schizophrenia; no PDSS observed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-133759","json":"https://secwatch.observer/filing/0001193125-24-133759.json","markdown":"https://secwatch.observer/filing/0001193125-24-133759.md","text":"https://secwatch.observer/filing/0001193125-24-133759.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000119312524133759/0001193125-24-133759-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000119312524133759/d801848d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T14:48:37.208017+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"56f0127c8b9496db532fb0bf5d4d3d0fb941f40e","claim":"TEVA PHARMACEUTICAL INDUSTRIES LTD reported the quarter ended March 31, 2024 results: revenue $3,819 million, EPS GAAP loss per share of $0.12. Guidance reaffirmed.","evidence_excerpt":"TEVA REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND REAFFIRMS 2024 FINANCIAL OUTLOOK • Generics business and AUSTEDO ® growth lead Q1 2024 performance. • Q1 2024 revenues of $3.8 billion reflect an increase of 5% in local currency terms, compared to Q1 2023. • Generics business growth across all regions – increased by 9% in local currency terms globally, compared","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818686/000119312524133759/0001193125-24-133759-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$3,819 million"},{"label":"EPS","value":"GAAP loss per share of $0.12"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}